参考文献:1.Jayasena CN, Franks S. The management of patients with polycystic ovary syndrome. Nat Rev Endocrinol. 2014;10(10):624–36. doi:10.1038/nrendo.2014.102 .CrossRef PubMed 2.Diamanti-Kandarakis E, Kandarakis H, Legro RS. The role of genes and environment in the etiology of PCOS. Endocrine. 2006;30(1):19–26. doi:10.1385/ENDO:30:1:19 .CrossRef PubMed 3.de Vet A, Laven JS, de Jong FH, Themmen AP, Fauser BC. Antimullerian hormone serum levels: a putative marker for ovarian aging. Fertil Steril. 2002;77(2):357–62. doi:10.1038/345167a0 .CrossRef PubMed 4.van Rooij IA, Broekmans FJ, Te VE, Fauser BC, Bancsi LF, de Jong FH, et al. Serum anti-Mullerian hormone levels: a novel measure of ovarian reserve. Hum Reprod. 2002;17(12):3065–71.CrossRef PubMed 5.Peluso C, Fonseca FL, Rodart IF, Cavalcanti V, Gastaldo G, Christofolini DM, et al. AMH: An ovarian reserve biomarker in assisted reproduction. Clin Chim Acta. 2014;437:175–82. doi:10.1016/j.cca.2014.07.029 .CrossRef PubMed 6.Durlinger AL, Visser JA, Themmen AP. Regulation of ovarian function: the role of anti-Mullerian hormone. Reproduction. 2002;124(5):601–9.CrossRef PubMed 7.Gruijters MJ, Visser JA, Durlinger AL, Themmen AP. Anti-Mullerian hormone and its role in ovarian function. Mol Cell Endocrinol. 2003;211(1–2):85–90.CrossRef PubMed 8.Durlinger AL, Gruijters MJ, Kramer P, Karels B, Kumar TR, Matzuk MM, et al. Anti-Mullerian hormone attenuates the effects of FSH on follicle development in the mouse ovary. Endocrinology. 2001;142(11):4891–9. doi:10.1210/endo.142.11.8486 .PubMed 9.Visser JA, Durlinger AL, Peters IJ, van den Heuvel ER, Rose UM, Kramer P, et al. Increased oocyte degeneration and follicular atresia during the estrous cycle in anti-Mullerian hormone null mice. Endocrinology. 2007;148(5):2301–8. doi:10.1210/en.2006-1265 .CrossRef PubMed 10.Homburg R, Crawford G. The role of AMH in anovulation associated with PCOS: a hypothesis. Hum Reprod. 2014;29(6):1117–21. doi:10.1093/humrep/deu076 .CrossRef PubMed 11.Pigny P, Jonard S, Robert Y, Dewailly D. Serum anti-Mullerian hormone as a surrogate for antral follicle count for definition of the polycystic ovary syndrome. J Clin Endocrinol Metab. 2006;91(3):941–5. doi:10.1210/jc.2005-2076 .CrossRef PubMed 12.Homburg R, Ray A, Bhide P, Gudi A, Shah A, Timms P, et al. The relationship of serum anti-Mullerian hormone with polycystic ovarian morphology and polycystic ovary syndrome: a prospective cohort study. Hum Reprod. 2013;28(4):1077–83. doi:10.1093/humrep/det015 .CrossRef PubMed 13.Urbanek M. The genetics of the polycystic ovary syndrome. Nat Clin Pract Endocrinol Metab. 2007;3(2):103–11. doi:10.1038/ncpendmet0400 .CrossRef PubMed 14.Kevenaar ME, Laven JS, Fong SL, Uitterlinden AG, de Jong FH, Themmen AP, et al. A functional anti-mullerian hormone gene polymorphism is associated with follicle number and androgen levels in polycystic ovary syndrome patients. J Clin Endocrinol Metab. 2008;93(4):1310–6. doi:10.1210/jc.2007-2205 .CrossRef PubMed 15.Kevenaar ME, Themmen AP, Laven JS, Sonntag B, Fong SL, Uitterlinden AG, et al. Anti-Mullerian hormone and anti-Mullerian hormone type II receptor polymorphisms are associated with follicular phase estradiol levels in normo-ovulatory women. Hum Reprod. 2007;22(6):1547–54. doi:10.1093/humrep/dem036 .CrossRef PubMed 16.Tian CH, Hu R, Jia ST, Lan SX, Tian JS, Wang FM. Association between gene polymorphism of Anti-mullerian hormone and its type receptor II and ovarian reserve. Acta Med Univ Sci Technol Huazhong. 2012;41(03):315–9. 17.Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod. 2004;19(1):41–7. 18.von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet. 2007;370(9596):1453–7. doi:10.1016/S0140-6736(07)61602-X .CrossRef 19.Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28(7):412–9.CrossRef PubMed 20.Xing X, Yang W, Yang Z. The diagnostic significance of homeostasismodel assessment of insulin resistance in metabolic syndrome among subjects with different glucose tolerance. Chin J Diabetes. 2004;12(03):31–5. 21.Sproul K, Jones MR, Mathur R, Azziz R, Goodarzi MO. Association study of four key folliculogenesis genes in polycystic ovary syndrome. BJOG. 2010;117(6):756–60. doi:10.1111/j.1471-0528.2010.02527.x .PubMedCentral CrossRef PubMed 22.Drummond AE. The role of steroids in follicular growth. Reprod Biol Endocrinol. 2006;4:16. doi:10.1186/1477-7827-4-16 .PubMedCentral CrossRef PubMed 23.Havelock JC, Rainey WE, Carr BR. Ovarian granulosa cell lines. Mol Cell Endocrinol. 2004;228(1–2):67–78. doi:10.1016/j.mce.2004.04.018 .CrossRef PubMed 24.Young JM, McNeilly AS. Theca: the forgotten cell of the ovarian follicle. Reproduction. 2010;140(4):489–504. doi:10.1530/REP-10-0094 .CrossRef PubMed 25.Wen X, Li D, Tozer AJ, Docherty SM, Iles RK. Estradiol, progesterone, testosterone profiles in human follicular fluid and cultured granulosa cells from luteinized pre-ovulatory follicles. Reprod Biol Endocrinol. 2010;8:117. doi:10.1186/1477-7827-8-117 .PubMedCentral CrossRef PubMed 26.Chang HM, Klausen C, Leung PC. Antimullerian hormone inhibits follicle-stimulating hormone-induced adenylyl cyclase activation, aromatase expression, and estradiol production in human granulosa-lutein cells. Fertil Steril. 2013;100(2):585–92. doi:10.1016/j.fertnstert.2013.04.019 .CrossRef PubMed 27.Detti L, Uhlmann RA, Lu M, Diamond MP, Saed GM, Fletcher NM, et al. Serum markers of ovarian reserve and ovarian histology in adult mice treated with cyclophosphamide in pre-pubertal age. J Assist Reprod Genet. 2013;30(11):1421–9. doi:10.1007/s10815-013-0087-x .PubMedCentral CrossRef PubMed 28.Homburg R. Androgen circle of polycystic ovary syndrome. Hum Reprod. 2009;24(7):1548–55. doi:10.1093/humrep/dep049 .CrossRef PubMed 29.Schuring AN, Schulte N, Sonntag B, Kiesel L. Androgens and insulin--two key players in polycystic ovary syndrome. recent concepts in the pathophysiology and genetics of polycystic ovary syndrome. Gynakol Geburtshilfliche Rundsch. 2008;48(1):9–15. doi:10.1159/000111465 .CrossRef PubMed 30.Buckler HM, Phillips SE, Cameron IT, Healy DL, Burger HG. Vaginal progesterone administration before ovulation induction with exogenous gonadotropins in polycystic ovarian syndrome. J Clin Endocrinol Metab. 1988;67(2):300–6. doi:10.1210/jcem-67-2-300 .CrossRef PubMed 31.Baillargeon JP, Carpentier A. Role of insulin in the hyperandrogenemia of lean women with polycystic ovary syndrome and normal insulin sensitivity. Fertil Steril. 2007;88(4):886–93. doi:10.1016/j.fertnstert.2006.12.055 .CrossRef PubMed 32.Neagu M, Cristescu C. Anti-Mullerian hormone--a prognostic marker for metformin therapy efficiency in the treatment of women with infertility and polycystic ovary syndrome. J Med Life. 2012;5(4):462–4.PubMedCentral PubMed
作者单位:Meng-Xue Zheng (1) Yan Li (2) Rong Hu (3) Fei-Miao Wang (3) Xiao-Mei Zhang (4) Bing Guan (4)
1. Ningxia Medical University, General Hospital of Ningxia Medical University, Yinchuan, Ningxia, 750004, China 2. Department of Gynecology, General Hospital of Ningxia Medical University, Yinchuan, Ningxia, 750004, China 3. Reproductive Medicine Center, Key Laboratory of Fertility Preservation and Maintenance of Ministry of Education, Ningxia Medical University, General Hospital of Ningxia Medical University, Yinchuan, Ningxia, 750004, China 4. Reproductive Medicine Center, Department of Obstetrics and Gynecology, Northern Jiangsu People’s Hospital, Yangzhou University, Yangzhou, 225001, China
刊物类别:Medicine
刊物主题:Medicine & Public Health Gynecology Developmental Biology Human Genetics
出版者:Springer Netherlands
ISSN:1573-7330
文摘
Purpose The objective of the study was to investigate whether genetic polymorphisms of the anti-Müllerian hormone (AMH) and its specific receptor anti-Müllerian hormone type II receptor (AMHRII) were associated with the hormone disorder and phenotype of polycystic ovary syndrome (PCOS).